Redeye provides an update on Annexin after the company’s Q3 report, which held no significant surprises. NEXUS is now fully recruited, and we see the coming months, with DR and RVO data, an FDA meeting and topline data in Q1 2027, as important steps towards a licensing agreement.
LÄS MER
